SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ekman C. J.) ;srt2:(2010-2014)"

Sökning: WFRF:(Ekman C. J.) > (2010-2014)

  • Resultat 41-50 av 51
  • Föregående 1234[5]6Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Holgersson, Georg, et al. (författare)
  • Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer
  • 2011
  • Ingår i: European Journal of Cancer. - Elsevier. - 1879-0852. ; 47:16, s. 2415-2421
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of the present study was to evaluate the potential predictive value of histology in non-small cell lung cancer (NSCLC) treated with curatively intended radiotherapy. In a collaborative effort among all the Swedish Oncology Departments, clinical data were collected for 1146 patients with a diagnosed non-small cell lung cancer subjected to curatively intended irradiation (>= 50 Gy) during the years 1990 to 2000. The included patients were identified based on a manual search of all medical and radiation charts at the oncology departments from which the individual patient data were collected. Only patients who did not have a histological diagnosis date and death date/last follow-up date were excluded (n = 141). Among the 1146 patients with non-small cell carcinoma eligible for analysis, 919 were diagnosed with either adenocarcinoma (n = 323) or squamous cell carcinoma (n = 596) and included in this study. The median survival for the 919 patients was 14.8 months, while the 5-year survival rate was 9.5%. Patients with adenocarcinoma had a significantly better overall survival compared with patients with squamous cell carcinoma (p = 0.0062, log-rank test). When comparing different stages, this survival benefit was most pronounced for stages IIA-IIB (p<0.0001, log-rank test). The difference in survival between the two histological groups was statistically significant in a univariate Cox analysis (p = 0.0063) as well as in two multivariate Cox analyses including demographic and treatment variables (p = 0.037 and p = 0.048, respectively). In this large population based retrospective study we describe for the first time that patients with adenocarcinoma have a better survival after curatively intended radiation therapy in comparison with squamous cell carcinoma patients, particularly those with clinical stages IIA-IIB. (C) 2011 Elsevier Ltd. All rights reserved.
  •  
42.
  •  
43.
  •  
44.
  •  
45.
  •  
46.
  •  
47.
  • Nilsson, A. G., et al. (författare)
  • Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
  • 2014
  • Ingår i: European Journal of Endocrinology. - 0804-4643 .- 1479-683X. ; 171:3, s. 369-377
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objective: The objective was to assess the long-term safety profile of dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). Design: Randomised, open-label, crossover trial of DR-HC or thrice-daily hydrocortisone for 3 months each (stage 1) followed by two consecutive, prospective, open-label studies of DR-HC for 6 months (stage 2) and 18 months (stage 3) at five university clinics in Sweden. Methods: Sixty-four adults with primary AI started stage 1, and an additional 16 entered stage 3. Patients received DR-HC 20-40 mg once daily and hydrocortisone 20-40 mg divided into three daily doses (stage 1 only). Main outcome measures were adverse events (AEs) and intercurrent illness (self-reported hydrocortisone use during illness). Results: In stage 1, patients had a median 1.5 (range, 1-9) intercurrent illness events with DR-HC and 1.0 (1-8) with thrice-daily hydrocortisone. AEs during stage 1 were not related to the cortisol exposure-time profile. The percentage of patients with one or more AEs during stage 1 (73.4% with DR-HC; 65.6% with thrice-daily hydrocortisone) decreased during stage 2, when all patients received DR-HC (51% in the first 3 months; 54% in the second 3 months). In stages 1-3 combined, 19 patients experienced 27 serious AEs, equating to 18.6 serious AEs/100 patient-years of DR-HC exposure. Conclusions: This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy. European Journal of Endocrinology</p>
  •  
48.
  • Nilsson, A G, et al. (författare)
  • Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
  • 2014
  • Ingår i: European Journal of Endocrinology. - 0804-4643 .- 1479-683X. ; 171:3, s. 369-377
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>OBJECTIVE:</strong> The objective was to assess the long-term safety profile of dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI).</p><p><strong>DESIGN:</strong> Randomised, open-label, crossover trial of DR-HC or thrice-daily hydrocortisone for 3 months each (stage 1) followed by two consecutive, prospective, open-label studies of DR-HC for 6 months (stage 2) and 18 months (stage 3) at five university clinics in Sweden.</p><p><strong>METHODS:</strong> Sixty-four adults with primary AI started stage 1, and an additional 16 entered stage 3. Patients received DR-HC 20-40 mg once daily and hydrocortisone 20-40 mg divided into three daily doses (stage 1 only). Main outcome measures were adverse events (AEs) and intercurrent illness (self-reported hydrocortisone use during illness).</p><p><strong>RESULTS:</strong> In stage 1, patients had a median 1.5 (range, 1-9) intercurrent illness events with DR-HC and 1.0 (1-8) with thrice-daily hydrocortisone. AEs during stage 1 were not related to the cortisol exposure-time profile. The percentage of patients with one or more AEs during stage 1 (73.4% with DR-HC; 65.6% with thrice-daily hydrocortisone) decreased during stage 2, when all patients received DR-HC (51% in the first 3 months; 54% in the second 3 months). In stages 1-3 combined, 19 patients experienced 27 serious AEs, equating to 18.6 serious AEs/100 patient-years of DR-HC exposure.</p><p><strong>CONCLUSIONS:</strong> This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy.</p>
  •  
49.
  •  
50.
  • Rådsten-Ekman, Maria, et al. (författare)
  • Case-study evaluation of a low and vegetated noise barrier in an urban public space
  • 2011
  • Ingår i: Proceedings of Inter-Noise 2011. - Osaka, Japan: : The Institute of Noise Control Engineering of Japan and the Acoustical Society of Japan.
  • Konferensbidrag (övrigt vetenskapligt)abstract
    • <p>To improve the sound environment along a popular esplanade in Lyon, France, a 1 m high vegetated noise barrier was erected to protect against noise from an adjacent road. The barrier was made of a metallic structure, filled with a substrate on which 40 plants per square meter were grown on both sides. The effect of the barrier was evaluated by acoustic measurements conducted before and after the barrier was erected, as well as, by a questionnaire study in which pedestrians were asked to assess the sound environment both behind and at the side of the barrier. The barrier reduced the sound pressure level from about 67 to 62 dB (LAeq), at sitting height (1.2 m), 3.5 m from the roadside. Questionnaires responses (n = 349) from the same location showed that the barrier reduced road-traffic noise annoyance, and increased the overall quality of the sound environment by making it slightly calmer and slightly more pleasant. However, these effects were fairly small and the sound environment was still perceived as annoying by most of the respondents. Overall, the result thus suggested that the barrier made the sound environment better but not good. Further work will include detailed psychoacoustic analysis of the questionnaire data, as well as listening experiments using binaural recordings from the site.</p>
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-50 av 51
  • Föregående 1234[5]6Nästa
Åtkomst
fritt online (6)
Typ av publikation
tidskriftsartikel (43)
konferensbidrag (7)
rapport (1)
Typ av innehåll
refereegranskat (42)
övrigt vetenskapligt (9)
Författare/redaktör
Landen, M, (12)
Ekman, S, (11)
Bergqvist, M. (10)
Zetterberg, H (9)
Landén, Mikael, 1966 ... (9)
Ekman, CJ, (9)
visa fler...
Sellgren, C, (9)
Jakobsson, J. (9)
Blennow, K (8)
Bergstrom, S (7)
Johannsson, G (7)
Johansson, AGM, (7)
Wahlberg, J. (6)
Palsson, E (6)
Henriksson, R (5)
Ekman, C-J (5)
Bergqvist, Michael, (5)
Ekman, Simon (5)
Friesland, S, (5)
Friesland, Signe (5)
Svensson, J, (5)
Burman, P. (5)
Henriksson, Roger, (5)
Ekman, B (5)
Nyman, Jan (5)
Nyman, J (5)
Holgersson, Georg, (5)
Holgersson, G (5)
Ewers, Sven-Börje, (5)
Holgersson, Margaret ... (5)
Holgersson, M (5)
Helsing, Martin, (5)
Morth, C (5)
Loden, B. (5)
Bergstrom, Stefan (5)
Helsing, M (5)
Hoye, Even (5)
Morth, Charlotte (5)
Blystad, Thomas (5)
Loden, Britta (5)
Blennow, Kaj, 1958-, (4)
Ekman, Carl-Johan (4)
Zetterberg, Henrik, ... (4)
Ekman, M (4)
Erfurth, E. M. (4)
Karlsson, F. A. (4)
Berinder, K., (4)
Jakobsson, Joel, (4)
Mattsson, A F (4)
Holmer, H. (4)
visa färre...
Lärosäte
Karolinska Institutet (32)
Göteborgs universitet (20)
Lunds universitet (10)
Umeå universitet (3)
Stockholms universitet (3)
Uppsala universitet (2)
visa fler...
Linköpings universitet (2)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (51)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (30)
Naturvetenskap (6)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy